Literature DB >> 22737270

Regulation of IKKε Expression by Akt2 Isoform.

Soumya Krishnamurthy1, Alakananda Basu.   

Abstract

The inhibitor of κ B kinase-ε (IKKε), a breast cancer oncogene, functions as a transforming kinase by activating NF-κB. IKKε is often elevated in breast cancers in the absence of any gene amplification. Because Akt-mediated transformation was shown to require IKKε, we examined if Akt regulates IKKε level in breast cancer cells. Knockdown of Akt2, but not other Akt isoforms, decreased the basal and TNF-induced IKKε protein and mRNA level, and overexpression of Akt2 in MDA-MB-231 cells increased IKKε level. The decrease in IKKε level by Akt2 knockdown was not only restricted to MDA-MB-231 cells but was also observed in several other breast cancer cells, including HCC1937 and MCF-10CA1a cells. Knockdown of p65/RelA subunit of NF-κB decreased IKKε level and attenuated the increase in IKKε caused by Akt2 overexpression, suggesting that Akt2-mediated induction of IKKε involves NF-κB activation. Silencing of IKKε also decreased long-term clonogenic survival of Akt2-overexpressing MDA-MB-231 cells. Taken together, these results demonstrate for the first time that IKKε functions downstream of Akt2 to promote breast cancer cell survival.

Entities:  

Keywords:  Akt2; IKKε; NF-κB; TNF; breast cancer

Year:  2011        PMID: 22737270      PMCID: PMC3379568          DOI: 10.1177/1947601912444604

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  37 in total

1.  IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex.

Authors:  R T Peters; S M Liao; T Maniatis
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

2.  IκB-Kinase-ε (IKKε/IKKi/IκBKε) expression and localization in prostate cancer tissues.

Authors:  Benjamin Péant; Valérie Forest; Vincent Trudeau; Mathieu Latour; Anne-Marie Mes-Masson; Fred Saad
Journal:  Prostate       Date:  2011-01-26       Impact factor: 4.104

Review 3.  Emerging roles for the non-canonical IKKs in cancer.

Authors:  R R Shen; W C Hahn
Journal:  Oncogene       Date:  2010-11-01       Impact factor: 9.867

4.  IκB Kinase ε expression in pancreatic ductal adenocarcinoma.

Authors:  Anna Cheng; Jianping Guo; Evita Henderson-Jackson; Donghwa Kim; Mokenge Malafa; Domenico Coppola
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

Review 5.  The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy.

Authors:  James T Wu; John G Kral
Journal:  J Surg Res       Date:  2005-01       Impact factor: 2.192

6.  Induction of NF-kappaB by the Akt/PKB kinase.

Authors:  L P Kane; V S Shapiro; D Stokoe; A Weiss
Journal:  Curr Biol       Date:  1999-06-03       Impact factor: 10.834

Review 7.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

Authors:  Chikashi Nakanishi; Masakazu Toi
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

8.  Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C.

Authors:  A Basu; G R Akkaraju
Journal:  Biochemistry       Date:  1999-04-06       Impact factor: 3.162

9.  Inhibition of JNK by cellular stress- and tumor necrosis factor alpha-induced AKT2 through activation of the NF kappa B pathway in human epithelial Cells.

Authors:  Zeng-qiang Yuan; Richard I Feldman; Mei Sun; Nancy E Olashaw; Domenico Coppola; Gene E Sussman; Sue A Shelley; Santo V Nicosia; Jin Q Cheng
Journal:  J Biol Chem       Date:  2002-06-04       Impact factor: 5.157

10.  Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription.

Authors:  Holger Buss; Anneke Dörrie; M Lienhard Schmitz; Elke Hoffmann; Klaus Resch; Michael Kracht
Journal:  J Biol Chem       Date:  2004-10-15       Impact factor: 5.157

View more
  3 in total

1.  Diallyl disulfide inhibits TNFα induced CCL2 release through MAPK/ERK and NF-Kappa-B signaling.

Authors:  D Bauer; N Redmon; E Mazzio; E Taka; J S Reuben; A Day; S Sadrud-Din; H Flores-Rozas; K F A Soliman; S Darling-Reed
Journal:  Cytokine       Date:  2015-06-20       Impact factor: 3.861

Review 2.  Advances in IKBKE as a potential target for cancer therapy.

Authors:  Min Yin; Xin Wang; Jie Lu
Journal:  Cancer Med       Date:  2019-11-15       Impact factor: 4.452

Review 3.  IκB kinase ε (IKKε): a therapeutic target in inflammation and cancer.

Authors:  Kelly Verhelst; Lynn Verstrepen; Isabelle Carpentier; Rudi Beyaert
Journal:  Biochem Pharmacol       Date:  2013-01-17       Impact factor: 5.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.